Published in Front Mol Neurosci on May 13, 2014
Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder. Neurology (2015) 1.44
Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. J Neurochem (2016) 0.88
Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? J Parkinsons Dis (2016) 0.87
Phosphorylation of the FUS low-complexity domain disrupts phase separation, aggregation, and toxicity. EMBO J (2017) 0.87
Phosphoproteome Discovery in Human Biological Fluids. Proteomes (2016) 0.84
The Interplay between Alpha-Synuclein Clearance and Spreading. Biomolecules (2015) 0.84
Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein. Front Behav Neurosci (2015) 0.83
Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism. Front Genet (2014) 0.83
Phosphorylation modifies the molecular stability of β-amyloid deposits. Nat Commun (2016) 0.83
The Role of Oxidative Damage in the Pathogenesis and Progression of Alzheimer's Disease and Vascular Dementia. Oxid Med Cell Longev (2015) 0.81
Milk--A Nutrient System of Mammalian Evolution Promoting mTORC1-Dependent Translation. Int J Mol Sci (2015) 0.80
Poststroke Induction of α-Synuclein Mediates Ischemic Brain Damage. J Neurosci (2016) 0.80
Defying c-Abl signaling circuits through small allosteric compounds. Front Genet (2014) 0.79
Intracellular repair of oxidation-damaged α-synuclein fails to target C-terminal modification sites. Nat Commun (2016) 0.79
Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets (2014) 0.79
CK2-An Emerging Target for Neurological and Psychiatric Disorders. Pharmaceuticals (Basel) (2017) 0.78
Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment. Sci Rep (2016) 0.77
Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease. Biomolecules (2015) 0.77
Posttranslational Modifications and Clearing of α-Synuclein Aggregates in Yeast. Biomolecules (2015) 0.77
An Effective Method to Identify Shared Pathways and Common Factors among Neurodegenerative Diseases. PLoS One (2015) 0.76
The Proteasome Inhibition Model of Parkinson's disease. J Parkinsons Dis (2016) 0.76
Nuclear Tau and Its Potential Role in Alzheimer's Disease. Biomolecules (2016) 0.76
Phosphoproteomic profiling of selenate-treated Alzheimer's disease model cells. PLoS One (2014) 0.76
The effect of Scutellaria baicalensis stem-leaf flavonoids on spatial learning and memory in chronic cerebral ischemia-induced vascular dementia of rats. Acta Biochim Biophys Sin (Shanghai) (2016) 0.76
C-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α-Synuclein in a Yeast Model of Parkinson's Disease. PLoS Genet (2016) 0.76
Phosphorylation Interferes with Maturation of Amyloid-β Fibrillar Structure in the N Terminus. J Biol Chem (2016) 0.75
Dissecting the Molecular Pathway Involved in PLK2 Kinase-mediated α-Synuclein-selective Autophagic Degradation. J Biol Chem (2017) 0.75
Regulatory region genetic variation is associated with FYN expression in Alzheimer's disease. Neurobiol Aging (2016) 0.75
Neuroprotective Functions for the Histone Deacetylase SIRT6. Cell Rep (2017) 0.75
Regulation and targeting of enzymes mediating Parkinson's disease pathogenesis: focus on Parkinson's disease kinases, GTPases, and ATPases. Front Mol Neurosci (2014) 0.75
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice. Acta Neuropathol Commun (2017) 0.75
The incubation period of Alzheimer's disease and the timing of tau versus amyloid misfolding and spreading within the brain. Eur J Epidemiol (2016) 0.75
Loss of Tau protein affects the structure, transcription and repair of neuronal pericentromeric heterochromatin. Sci Rep (2016) 0.75
Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology. Alzheimers Res Ther (2016) 0.75
Critical Roles of Dual-Specificity Phosphatases in Neuronal Proteostasis and Neurological Diseases. Int J Mol Sci (2017) 0.75
Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases. Neurobiol Dis (2017) 0.75
Membrane Binding of Parkinson's Protein α-Synuclein: Effect of Phosphorylation at Positions 87 and 129 by the S to D Mutation Approach. Isr J Chem (2016) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature (2004) 11.82
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol (2004) 9.62
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (2006) 8.15
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (2004) 7.69
Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell (2010) 7.52
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.67
alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol (2002) 6.64
Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 6.17
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science (2000) 5.62
Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature (1999) 5.53
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (2007) 5.49
Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci (2001) 5.32
Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature (2010) 5.08
Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta (2010) 4.99
MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell (1997) 4.75
Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A (1988) 4.68
Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science (2001) 4.48
Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A (1988) 4.45
Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science (2003) 4.45
Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science (2001) 4.18
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem (2006) 4.06
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 3.79
Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (2003) 3.76
Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci (2009) 3.68
Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A (2000) 3.49
Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem (1984) 3.36
Epitopes that span the tau molecule are shared with paired helical filaments. Neuron (1988) 3.28
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron (2005) 3.20
The GSK3 hypothesis of Alzheimer's disease. J Neurochem (2007) 3.16
Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron (2010) 3.15
Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci (2007) 3.10
Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res (1989) 3.10
Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron (2003) 2.97
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci (2005) 2.91
Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci (2013) 2.90
Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A (2010) 2.86
Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature (1990) 2.79
PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell (2004) 2.78
The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci (2013) 2.78
Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron (2006) 2.66
Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci (2010) 2.66
Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J (2003) 2.64
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A (2005) 2.45
Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A (2003) 2.44
Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem (2003) 2.42
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med (2009) 2.39
Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med (2012) 2.39
Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.39
Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles. J Cell Sci (1999) 2.36
Critical role of CDK5 and Polo-like kinase 2 in homeostatic synaptic plasticity during elevated activity. Neuron (2008) 2.29
Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron (2002) 2.28
Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem (2000) 2.27
CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem (2003) 2.27
Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci (2004) 2.25
Polyglutamine protein aggregates are dynamic. Nat Cell Biol (2002) 2.21
Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci (2010) 2.20
Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol (2003) 2.20
Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One (2011) 2.19
Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem (2000) 2.19
Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron (2003) 2.17
The prion protein as a receptor for amyloid-beta. Nature (2010) 2.10
Multisite protein phosphorylation--from molecular mechanisms to kinetic models. FEBS J (2009) 2.10
Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem (1995) 2.09
Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol (1999) 2.08
Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem (1992) 2.04
Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A (2009) 2.04
Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet (2006) 2.03
The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun (2011) 2.00
The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A (2008) 2.00
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci (2010) 1.97
Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. Hum Mol Genet (2013) 1.94
Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem (2008) 1.94
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov (2007) 1.92
Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J Biol Chem (2003) 1.91
Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep (2002) 1.91
Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration? J Neurochem (2009) 1.91
Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm (Vienna) (2004) 1.89
Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol (2012) 1.89
Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry (1999) 1.88
Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol (2008) 1.87
Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem (2004) 1.84
Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci (2007) 1.82
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 1.82
Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology (2006) 1.81
Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc Natl Acad Sci U S A (2010) 1.81
GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry (2004) 1.79
G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol (2013) 1.77
Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell (2002) 1.76
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol (2013) 1.75